Literature DB >> 30992280

Engineering Multidimensional Evolutionary Forces to Combat Cancer.

Caroline E McCoach1,2, Trever G Bivona1,2,3.   

Abstract

With advances in technology and bioinformatics, we are now positioned to view and manage cancer through an evolutionary lens. This perspective is critical as our appreciation for the role of tumor heterogeneity, tumor immune compartment, and tumor microenvironment on cancer pathogenesis and evolution grows. Here, we explore recent knowledge on the evolutionary basis of cancer pathogenesis and progression, viewing tumors as multilineage, multicomponent organisms whose growth is regulated by subcomponent fitness relationships. We propose reconsidering some current tenets of the cancer management paradigm in order to take better advantage of crucial fitness relationships to improve outcomes of patients with cancer. SIGNIFICANCE: Tumor and tumor immune compartment and microenvironment heterogeneity, and their evolution, are critical disease features that affect treatment response. The impact and interplay of these components during treatment are viable targets to improve clinical response. In this article, we consider how tumor cells, the tumor immune compartment and microenvironment, and epigenetic factors interact and also evolve during treatment. We evaluate the convergence of these factors and suggest innovative treatment concepts that leverage evolutionary relationships to limit tumor growth and drug resistance. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 30992280      PMCID: PMC6497542          DOI: 10.1158/2159-8290.CD-18-1196

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  211 in total

Review 1.  Epigenetic targeting in pancreatic cancer.

Authors:  Jasmijn G M van Kampen; Monica A J Marijnissen-van Zanten; Femke Simmer; Winette T A van der Graaf; Marjolijn J L Ligtenberg; Iris D Nagtegaal
Journal:  Cancer Treat Rev       Date:  2014-01-03       Impact factor: 12.111

2.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.

Authors:  C Zeller; W Dai; N L Steele; A Siddiq; A J Walley; C S M Wilhelm-Benartzi; S Rizzo; A van der Zee; J A Plumb; R Brown
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

3.  Modulation of growth of a human prostatic cancer cell line (PC-3) in agar culture by normal human lung fibroblasts.

Authors:  D Kirk; M F Szalay; M E Kaighn
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

4.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

Authors:  Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

5.  Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.

Authors:  Kalyani Narra; Stefanie R Mullins; Hyung-Ok Lee; Brenda Strzemkowski-Brun; Kimberly Magalong; Victoria J Christiansen; Patrick A McKee; Brian Egleston; Steven J Cohen; Louis M Weiner; Neal J Meropol; Jonathan D Cheng
Journal:  Cancer Biol Ther       Date:  2007-08-14       Impact factor: 4.742

6.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

7.  Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.

Authors:  Azusa Tanimoto; Shinji Takeuchi; Sachiko Arai; Koji Fukuda; Tadaaki Yamada; Xavier Roca; S Tiong Ong; Seiji Yano
Journal:  Clin Cancer Res       Date:  2016-12-16       Impact factor: 12.531

Review 8.  Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma.

Authors:  Erik F Hensen; Jean-Pierre Bayley
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

9.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

10.  Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.

Authors:  Boe S Sorensen; Lin Wu; Wen Wei; Julie Tsai; Britta Weber; Ebba Nexo; Peter Meldgaard
Journal:  Cancer       Date:  2014-08-07       Impact factor: 6.860

View more
  8 in total

Review 1.  Towards precision oncology with patient-derived xenografts.

Authors:  Eugenia R Zanella; Elena Grassi; Livio Trusolino
Journal:  Nat Rev Clin Oncol       Date:  2022-09-23       Impact factor: 65.011

Review 2.  Treating Cancer as an Invasive Species.

Authors:  Javad Noorbakhsh; Zi-Ming Zhao; James C Russell; Jeffrey H Chuang
Journal:  Mol Cancer Res       Date:  2019-09-16       Impact factor: 5.852

3.  Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer.

Authors:  Wenhui Li; Ming Xu; Yu Li; Ziwei Huang; Jun Zhou; Qiuyang Zhao; Kehao Le; Fang Dong; Cheng Wan; Pengfei Yi
Journal:  J Transl Med       Date:  2020-02-18       Impact factor: 5.531

4.  Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.

Authors:  Ashley Maynard; Caroline E McCoach; Julia K Rotow; Lincoln Harris; Franziska Haderk; D Lucas Kerr; Elizabeth A Yu; Erin L Schenk; Weilun Tan; Alexander Zee; Michelle Tan; Philippe Gui; Tasha Lea; Wei Wu; Anatoly Urisman; Kirk Jones; Rene Sit; Pallav K Kolli; Eric Seeley; Yaron Gesthalter; Daniel D Le; Kevin A Yamauchi; David M Naeger; Sourav Bandyopadhyay; Khyati Shah; Lauren Cech; Nicholas J Thomas; Anshal Gupta; Mayra Gonzalez; Hien Do; Lisa Tan; Bianca Bacaltos; Rafael Gomez-Sjoberg; Matthew Gubens; Thierry Jahan; Johannes R Kratz; David Jablons; Norma Neff; Robert C Doebele; Jonathan Weissman; Collin M Blakely; Spyros Darmanis; Trever G Bivona
Journal:  Cell       Date:  2020-08-20       Impact factor: 41.582

5.  A mathematical study on the drug resistant virus emergence with HIV/AIDS treatment cases.

Authors:  Hyeygjeon Chang
Journal:  Heliyon       Date:  2021-01-09

6.  Massively parallel quantification of phenotypic heterogeneity in single-cell drug responses.

Authors:  Benjamin B Yellen; Jon S Zawistowski; Eric A Czech; Caleb I Sanford; Elliott D SoRelle; Micah A Luftig; Zachary G Forbes; Kris C Wood; Jeff Hammerbacher
Journal:  Sci Adv       Date:  2021-09-17       Impact factor: 14.136

7.  Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.

Authors:  Moiez Ali; Min Lu; Hazel Xiaohui Ang; Ryan S Soderquist; Christine E Eyler; Haley M Hutchinson; Carolyn Glass; Christopher F Bassil; Omar M Lopez; D Lucas Kerr; Christina J Falcon; Helena A Yu; Aaron N Hata; Collin M Blakely; Caroline E McCoach; Trever G Bivona; Kris C Wood
Journal:  Sci Transl Med       Date:  2022-03-30       Impact factor: 19.319

8.  Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology.

Authors:  Timothy M Errington; Alexandria Denis; Anne B Allison; Renee Araiza; Pedro Aza-Blanc; Lynette R Bower; Jessica Campos; Heidi Chu; Sarah Denson; Cristine Donham; Kaitlyn Harr; Babette Haven; Elizabeth Iorns; Jennie Kwok; Elysia McDonald; Steven Pelech; Nicole Perfito; Amanda Pike; Darryl Sampey; Michael Settles; David A Scott; Vidhu Sharma; Todd Tolentino; Angela Trinh; Rachel Tsui; Brandon Willis; Joshua Wood; Lisa Young
Journal:  Elife       Date:  2021-12-07       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.